Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration.
Liu E., Sun Y., Yang L., Jiang H., Sun F., Chen L.
Animal Study on Back Pain, Disc Degeneration, Scar, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Front Pharmacol (2025)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40356987
- PMCID
- PMC12067415
- DOI
- 10.3389/fphar.2025.1583635
- Citations
- 1
Abstract (original English)
Background Intervertebral disc degeneration (IDD) significantly contributes to low back pain (LBP), yet effective treatment options are scarce. BSHXF, a classical traditional Chinese medicine formula, demonstrates dual pharmacological actions: tonifying kidneys, strengthening bones, activating blood circulation, and resolving stasis. It has been widely used in IDD management. Given its potential, combining BSHXF with miRNA regulation and stem cell therapy may enhance therapeutic outcomes by targeting molecular and cellular pathways underlying IDD pathogenesis. Aim of the study IDD is recognized as one of the primary causes of low back pain, yet effective therapeutic interventions for this condition remain limited. This study explores the role of BSHXF drug-containing serum combined with adipose-derived stem cells (ADSCs) in slowing IDD progression via the miR-199a-3p/TGF-β/Smad signaling pathway. By comprehensively investigating the synergistic effects of this combination therapy, we aim to propose a novel multi-target strategy that addresses the complex pathogenesis of IDD. Materials and methods This study employed a combination of in vivo and in vitro models. An IDD model was induced in rat caudal intervertebral discs through needle puncture, while an oxidative stress-induced ADSCs injury model was created in vitro using tert-butyl hydroperoxide (T-BHP). Cell viability was me
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level ASystematic ReviewEurope PMC
Role of Platelet-Rich Plasma (PRP) in the Management of Stage III and IV Degenerative Disc Disease
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
- 2025
Cureus1 citations - Level ASystematic ReviewPubMed
Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).
Systematic Review on Back Pain, Scar, published in Pain Physician (2025) — summary generated from the PubMed abstract.
- 2025
Pain Physician - Level AMeta-analysisPubMed
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Meta-analysis with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine1 citations - Level ASystematic ReviewEurope PMC
Sirtuins in intervertebral disc degeneration: current understanding
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Mol Med (2024) — summary generated from the PubMed abstract.
- 2024
Mol Med11 citations - Level ASystematic ReviewEurope PMC
A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis
Systematic Review on Back Pain, Disc Degeneration, published in JOR Spine (2024) — summary generated from the PubMed abstract.
- 2024
JOR Spine22 citations